Advertisement

Impact of Acquisition Method and Region of Interest Placement on Inter-observer Agreement and Measurement of Tumor Response to Targeted Therapy Using Dynamic Contrast-Enhanced Ultrasound

      Abstract

      This study evaluated the impact of different acquisition methods, user-directed region of interest placement and post-processing steps on the quantification of dynamic contrast-enhanced ultrasound measurements of blood volume in 29 patients with renal cancer, pre- and post-treatment. Specifically, we compared tumor quantification using multiple planes versus a single plane, breathhold versus free breathing and large region of interest versus a region targeting the area of highest vascularity. Performance was evaluated using area under the receiver operating characteristic curves to identify the method that best predicts progression-free survival. The intra-class correlation coefficient was also used to investigate how the same parameters affect inter-observer agreement. Of the different methods used to quantify blood volume in this study, the combination that had the highest level of inter-observer agreement (intra-class correlation coefficient = 0.8–0.97) and was the best predictor of progression-free survival was the change in blood volume measured (area under receiver operating characteristic curve = 0.77, p = 0.04) by a multiplane average, acquired during quiet breathing, quantified using a region of interest that encompassed the entire tumor.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Ultrasound in Medicine and Biology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Arditi M.
        • Frinking P.J.
        • Zhou X.
        • Rognin N.G.
        A new formalism for the quantification of tissue perfusion by the destruction–replenishment method in contrast ultrasound imaging.
        IEEE Trans Ultrason Ferroelectr Freq Control. 2006; 53: 1118-1129
        • Averkiou M.A.
        • Lampaskis M.
        • Kyriakopoulou K.
        • Skarlos D.
        • Klouvas G.
        • Strouthos C.
        • Leen E.L.
        Quantification of tumor microvascularity with respiratory gated contrast enhanced ultrasound for monitoring therapy.
        Ultrasound Med Biol. 2010; 36: 68-77
        • Choi H.
        • Charnsangavej C.
        • Faria S.C.
        • Macapinlac H.A.
        • Burgess M.A.
        • Patel S.R.
        • Chen L.L.
        • Podoloff D.A.
        • Benjamin R.S.
        Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria.
        J Clin Oncol. 2007; 25: 1753-1759
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • Schwartz L.H.
        • Sargent D.
        • Ford R.
        • Dancey J.
        • Arbuck S.
        • Gwyther S.
        • Mooney M.
        • Rubinstein L.
        • Shankar L.
        • Dodd L.
        • Kaplan R.
        • Lacombe D.
        • Verweij J.
        New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Gerlinger M.
        • Rowan A.
        • Horswell S.
        • Larkin J.
        • Endesfelder D.
        • Gronroos E.
        • Martinez P.
        • Matthews N.
        • Stewart A.
        • Tarpey P.
        Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
        N Engl J Med. 2012; 366: 883-892
        • Hahn O.M.
        • Yang C.
        • Medved M.
        • Karczmar G.
        • Kistner E.
        • Karrison T.
        • Manchen E.
        • Mitchell M.
        • Ratain M.J.
        • Stadler W.M.
        Dynamic Contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
        J Clin Oncol. 2008; 26: 4572-4578
        • Han K.S.
        • Jung D.C.
        • Choi H.J.
        • Jeong M.S.
        • Cho K.S.
        • Joung J.Y.
        • et al.
        Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy.
        Cancer. 2010; 116: 2332-2342
        • Hoyt K.
        • Sorace A.
        • Saini R.
        Volumetric contrast-enhanced ultrasound imaging to assess early response to apoptosis-inducing anti-death receptor 5 antibody therapy in a breast cancer animal model.
        J Ultrasound Med. 2012; 31: 1759-1766
        • Hudson J.M.
        • Karshafian R.
        • Burns P.N.
        Quantification of flow using ultrasound and microbubbles: A disruption replenishment model based on physical principles.
        Ultrasound Med Biol. 2009; 35: 2007-2020
        • Hudson J.M.
        • Williams R.
        • Lloyd B.
        • Atri M.
        • Kim T.K.
        • Bjarnason G.A.
        • Burns P.N.
        Improved flow measurement using microbubble contrast agents and disruption–replenishment: Clinical application to tumour monitoring.
        Ultrasound Med Biol. 2011; 37: 1210-1221
        • Lassau N.
        • Bonastre J.
        • Kind M.
        • Vilgrain V.
        • Lacroix J.
        • Cuinet M.
        • Taieb S.
        • Aziza R.
        • Sarran A.
        • Labbe-Devilliers C.
        • Gallix B.
        • Lucidarme O.
        • Ptak Y.
        • Rocher L.
        • Caquot L.M.
        • Chagnon S.
        • Marion D.
        • Luciani A.
        • Feutray S.
        • Uzan-Augui J.
        • Coiffier B.
        • Benastou B.
        • Koscielny S.
        Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: The French multicenter Support for Innovative and Expensive Techniques study.
        Invest Radiol. 2014; 49: 794-800
        • Lassau N.
        • Chami L.
        • Benatsou B.
        • Peronneau P.
        • Roche A.
        Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: A new diagnostic tool to evaluate the early effects of antiangiogenic treatment.
        Eur Radiol. 2007; 17: F89-F98
        • Lassau N.
        • Chami L.
        • Koscielny S.
        • Chebil M.
        • Massard C.
        • Benatsou B.
        • Bidault S.
        • Cioffi A.
        • Blay J.Y.
        • Le Cesne A.
        Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib.
        Invest New Drugs. 2012; 30: 765-771
        • Lassau N.
        • Chapotot L.
        • Benatsou B.
        • Vilgrain V.
        • Kind M.
        • Lacroix J.
        • Cuinet M.
        • Taieb S.
        • Aziza R.
        • Sarran A.
        • Labbe C.
        • Gallix B.
        • Lucidarme O.
        • Ptak Y.
        • Rocher L.
        • Caquot L.M.
        • Chagnon S.
        • Marion D.
        • Luciani A.
        • Uzan-Augui J.
        • Koscielny S.
        Standardization of dynamic contrast-enhanced ultrasound for the evaluation of antiangiogenic therapies: The French multicenter Support for Innovative and Expensive Techniques study.
        Invest Radiol. 2012; 47: 711-716
        • Lavisse S.
        • Lejeune P.
        • Rouffiac V.
        • Elie N.
        • Bribes E.
        • Demers B.
        • Vrignaud P.
        • Bissery M.-C.
        • Brulé A.
        • Koscielny S.
        • Péronneau P.
        • Lassau N.
        Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography.
        Invest Radiol. 2008; 43: 100-111
        • Lee J.
        • Koh D.
        • Ong C.N.
        Statistical evaluation of agreement between two methods for measuring a quantitative variable.
        Comput Biol Med. 1989; 19: 61-70
        • Mains J.R.
        • Donskov F.
        • Pedersen E.M.
        • Madsen H.H.
        • Rasmussen F.
        Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic renal cell carcinoma: Preliminary results from the Danish Renal Cancer Group study—1.
        Invest Radiol. 2014; 49: 601-607
        • Mancuso M.
        • Davis R.
        • Norberg S.
        • O'Brien S.
        • Sennino B.
        • Nakahara T.
        • Yao V.
        • Inai T.
        • Brooks P.
        • Freimark B.
        Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
        J Clin Invest. 2006; 116: 2610-2621
        • Motzer R.J.
        • Hutson T.E.
        • Tomczak P.
        • Michaelson M.D.
        • Bukowski R.M.
        • Oudard S.
        • Negrier S.
        • Szczylik C.
        • Pili R.
        • Bjarnason G.A.
        • Garcia-del-Muro X.
        • Sosman J.A.
        • Solska E.
        • Wilding G.
        • Thompson J.A.
        • Kim S.T.
        • Chen I.
        • Huang X.
        • Figlin R.A.
        Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
        J Clin Oncol. 2009; 27: 3584-3590
        • Nathan P.
        • Vinayan A.
        • Stott D.
        • Juttla J.
        • Goh V.
        CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.
        Cancer Biol Ther. 2010; 9: 15-19
        • Panebianco V.
        • Iacovelli R.
        • Barchetti F.
        • Altavilla A.
        • Forte V.
        • Sciarra A.
        • Cortesi E.
        • Catalano C.
        Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma.
        Anticancer Res. 2013; 33: 5663-5666
        • Rognin N.
        • Frinking P.J.
        • Costa M.
        • Arditi M.
        In-vivo perfusion quantification by contrast ultrasound: Validation of the use of linearized video data vs. raw RF data.
        Proc IEEE Ultrason Symp. 2008; : 1690-1693
        • Tang M.X.
        • Mulvana H.
        • Gauthier T.
        • Lim A.
        • Cosgrove D.
        • Eckersley R.
        • Stride E.
        Quantitative contrast-enhanced ultrasound imaging: A review of sources of variability.
        Interface Focus. 2011; 1: 520
        • Therasse P.
        • Arbuck S.G.
        • Eisenhauer E.A.
        • Wanders J.
        • Kaplan R.S.
        • Rubinstein L.
        • Verweij J.
        • Van Glabbeke M.
        • van Oosterom A.T.
        • Christian M.C.
        • Gwyther S.G.
        New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
        J Natl Cancer Inst. 2000; 92: 205-216
        • Williams R.
        • Hudson J.M.
        • Lloyd B.A.
        • Sureshkumar A.R.
        • Lueck G.
        • Milot L.
        • Atri M.
        • Bjarnason G.A.
        • Burns P.N.
        Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: A proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.
        Radiology. 2011; 260: 581-590